Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an electrolyte supplement used to treat or prevent hypokalemia. It is available in various formulations, including oral tablets, capsules, solutions, and intravenous solutions. ## Primary Indications * Treatment of hypokalemia (serum potassium < 3.5 mEq/L). * Prevention of hypokalemia, particularly in patients receiving diuretics or other medications that may deplete potassium. ## Adult Dosing * **Treatment of Hypokalemia:** * Oral: Typically 20-100 mEq per day, divided into 2-4 doses. Severe hypokalemia may require higher doses. Maximum oral dose is generally 100 mEq/day, though higher doses may be used under close ECG and serum potassium monitoring. * Intravenous: Dosing is highly individualized based on serum potassium levels and clinical status. Generally administered as a continuous infusion. **Never administer IV KCl undiluted or as a rapid bolus.** Maximum recommended infusion rate is typically 10-20 mEq/hour. Higher rates (up to 40 mEq/hour) may be used in life-threatening hypokalemia but require continuous ECG monitoring and central venous access. Total daily IV dose typically ranges from 40-100 mEq, but can be higher in severe cases. * **Prevention of Hypokalemia:** * Oral: Typically 20-40 mEq per day, divided into 1-2 doses. *Specific dosing, especially for IV administration, depends on local protocols and patient-specific factors.* ## Pediatric Dosing * Dosing is weight-based and depends on serum potassium levels. * Oral: Typically 1-3 mEq/kg/day, divided into 2-4 doses. Maximum daily dose is generally 100 mEq or as per local protocol. * Intravenous: Dosing is highly individualized. Often initiated at 0.5-1 mEq/kg/dose or as a continuous infusion. Maximum infusion rate is generally 10-20 mEq/hour. **Never administer IV KCl undiluted or as a rapid bolus.** *Dosing in neonates and critically ill children requires careful calculation and close monitoring.* ## Dose Adjustments * **Renal Impairment:** Dose reduction is necessary. Monitor potassium closely. In severe renal impairment, potassium supplementation may be contraindicated. ## Contraindications * Hyperkalemia (serum potassium > 5.0 mEq/L). * Conditions that may predispose to hyperkalemia, such as Addison's disease, untreated Addison's disease, chronic renal failure, or certain gastrointestinal disorders. * Known hypersensitivity to potassium chloride. ## Adverse Effects * **Gastrointestinal:** Nausea, vomiting, abdominal pain, diarrhea, ulceration, bleeding, perforation of the esophagus, stomach, and small intestine (particularly with slow-release oral formulations). * **Cardiovascular:** Arrhythmias, cardiac arrest (especially with rapid IV administration or hyperkalemia). * **Other:** Hyperkalemia. ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors and Angiotensin II Receptor Blockers (ARBs):** Increased risk of hyperkalemia. * **NSAIDs:** May impair potassium excretion, increasing the risk of hyperkalemia. * **Digitalis glycosides:** Hyperkalemia can potentiate digitalis toxicity; hypokalemia can increase the risk of digitalis toxicity. ## Monitoring * **Serum potassium levels:** Monitor frequently, especially during initiation of therapy, dose changes, and in patients with renal impairment or those at risk for hyperkalemia. * **ECG:** Especially important for patients receiving IV potassium or those with significant hypokalemia or hyperkalemia. * **Renal function:** Monitor BUN and creatinine. * **Signs and symptoms of hyperkalemia:** Weakness, fatigue, paresthesias, ECG changes. * **Signs and symptoms of hypokalemia:** Muscle cramps, weakness, fatigue, constipation, arrhythmias. ## Clinical Pearls * Oral potassium chloride can be irritating to the gastrointestinal tract. Administer with food or fluids to minimize gastric upset. * Slow-release oral formulations are associated with a higher risk of gastrointestinal ulceration and perforation. * Intravenous potassium chloride must be diluted and administered via a central or peripheral line depending on concentration and infusion rate. **Never give IV KCl as a bolus injection.** * Rapid IV administration of potassium can be fatal. * Ensure adequate renal function before administering potassium supplements. **Disclaimer:** This information is intended for clinical decision-making and does not replace a thorough review of the current prescribing information and relevant literature. Always verify current drug information with official sources before prescribing or administering any medication.